Literature DB >> 24289764

Investigation of in-vitro susceptibility of multidrug-resistant Acinetobacter baumannii strains isolated from clinical specimens to tigecycline.

Tekin Tas1, Esra Kocoglu, Zafer Mengeloglu, Ozlem Bucak, Seyda Karabörk.   

Abstract

The management of infections due to A. baumannii is difficult because of rapidly developing resistance, however, tigecycline, a glycylcycline antimicrobial, is in use for several years. In the present study, it was aimed to determine the susceptibility rates of A. baumannii to tigecycline. A total of 90 A. baumanni isolates were tested using three methods such as disk diffusion, broth microdilution, and E-test. The MIC50 and MIC90 values and the MIC range were found as 2 µg/ml, 4 µg/ml, and 0.1-8 µg/ml by microdilution; and 2 µg/ml, 6 µg/ml, and 0.1-12 µg/ml by E-test, respectively. There were a few major errors as well as the minor rates were all high as between 35.7%-46.7%. The accuracy rates between the methods were low as 53.3% (48/90) between disk diffusion and E-test, 51.1% (46/90) between disk diffusion and microdilution, and 60.0% (54/90) between E-test and microdilution. In the ROC curve analysis, an inhibition zone diameter of susceptibility breakpoint of 21.5 mm had sensitivity between 68.8%-88.9%; specificity between 81.9%-87.9%; and accuracy between 80.0%-83.33%. An analysis based on EUCAST's non-species breakpoints, the MIC tests showed higher accuracy with a rate of 96.7%, however, performance of disk diffusion got worse as lower than 25%. In conclusion, we showed that the reliability of the methods even did not remain as high as the past. Our study presented that none of three methods revealed reliable results in determination of susceptibility of A. baumanni to tigecycline, so the clinical response should be followed up carefully in such cases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24289764      PMCID: PMC4334001          DOI: 10.17305/bjbms.2013.2338

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  23 in total

1.  In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals.

Authors:  Maria Souli; Flora V Kontopidou; Evangelos Koratzanis; Anastasia Antoniadou; Efthimia Giannitsioti; Pinelopi Evangelopoulou; Sofia Kannavaki; Helen Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Comparative in vitro activities of tigecycline and 11 other antimicrobial agents against 215 epidemiologically defined multidrug-resistant Acinetobacter baumannii isolates.

Authors:  Harald Seifert; Danuta Stefanik; Hilmar Wisplinghoff
Journal:  J Antimicrob Chemother       Date:  2006-09-14       Impact factor: 5.790

3.  EUCAST technical note on tigecycline.

Authors: 
Journal:  Clin Microbiol Infect       Date:  2006-11       Impact factor: 8.067

4.  Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial.

Authors:  Diane C Halstead; Joan Abid; Michael J Dowzicky
Journal:  J Infect       Date:  2007-01-23       Impact factor: 6.072

5.  The susceptibility to tigecycline of Acinetobacter spp. may vary depending on the methodology used.

Authors:  Mariela S Zárate; Gisela Serruto; Jorgelina Smayevsky
Journal:  Int J Infect Dis       Date:  2009-12-23       Impact factor: 3.623

6.  [Comparison of disc diffusion, E-test, and broth microdilution methods for the determination of resistance to colistin, polymyxin B, and tigecycline in multi-resistant Acinetobacter baumannii isolates].

Authors:  F Ebru Ozgür Akin; Ayşen Bayram; Iclal Balci
Journal:  Mikrobiyol Bul       Date:  2010-04       Impact factor: 0.622

7.  Antimicrobial susceptibility of extended-spectrum beta-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial.

Authors:  Daryl J Hoban; Samuel K Bouchillon; Michael J Dowzicky
Journal:  Diagn Microbiol Infect Dis       Date:  2007-04       Impact factor: 2.803

8.  In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.

Authors:  Marc H Scheetz; Chao Qi; John R Warren; Michael J Postelnick; Teresa Zembower; Arlene Obias; Gary A Noskin
Journal:  Antimicrob Agents Chemother       Date:  2007-02-16       Impact factor: 5.191

9.  In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii.

Authors:  Seth T Housman; Mao Hagihara; David P Nicolau; Joseph L Kuti
Journal:  J Antimicrob Chemother       Date:  2013-05-24       Impact factor: 5.790

Review 10.  The emergence of clinical resistance to tigecycline.

Authors:  Yan Sun; Yun Cai; Xu Liu; Nan Bai; Beibei Liang; Rui Wang
Journal:  Int J Antimicrob Agents       Date:  2012-11-03       Impact factor: 5.283

View more
  3 in total

1.  Active efflux pump adeB is involved in multidrug resistance of Acinetobacter baumannii induced by antibacterial agents.

Authors:  Tingting Zhang; Min Wang; Yixin Xie; Xianping Li; Zhihui Dong; Yanhua Liu; Ling Wang; Min Yang; Huan Song; Hong Cao; Wei Cao
Journal:  Exp Ther Med       Date:  2017-02-21       Impact factor: 2.447

2.  In vitro potential of Lycosin-I as an alternative antimicrobial drug for treatment of multidrug-resistant Acinetobacter baumannii infections.

Authors:  Ling Wang; Yong-Jun Wang; Yin-Yin Liu; Hui Li; Ling-Xia Guo; Zhong-Hua Liu; Xiao-Liu Shi; Min Hu
Journal:  Antimicrob Agents Chemother       Date:  2014-09-08       Impact factor: 5.191

3.  Evaluation of Preclinical and Clinical Studies Published in Medical Journals of Bosnia and Herzegovina: Methodology Issues.

Authors:  Slobodan M Jankovic; Izet Masic
Journal:  Acta Inform Med       Date:  2020-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.